SAN DIEGO–(BUSINESS WIRE)–Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the third quarter ended September 30, 2026, together with other business updates. Key Financial Results: Quarterly revenue of $45.9 million, Net loss of $(24.0) million, and Adjusted EBITDA of $5.8 million; Full year 2026 revenue guidance range increased to $212.0 million to $
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
